<DOC>
	<DOCNO>NCT00730379</DOCNO>
	<brief_summary>This study do find best tolerate dose ridaforolimus dalotuzumab patient advance cancer observe anti-tumor activity patient .</brief_summary>
	<brief_title>A Combination Study With Ridaforolimus ( MK8669 ) Dalotuzumab ( MK0646 ) Patients With Advanced Cancer ( 8669-004 )</brief_title>
	<detailed_description>Ridaforolimus ( MK8669/AP23573 ) also know deforolimus May 2009</detailed_description>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>You must confirm metastatic advanced cancer respond standard therapy standard therapy exist In Part C , patient must diagnosis advanced metastatic colorectal adenocarcinoma nonsmall cell lung cancer , must receive least 1 three prior systemic therapy treatment regimens You must age 18 year old You must ECOG status performance 0 1 You must good organ function You must willing skin and/or tumor biopsy You cancer treatment within 4 week prior enter study still bad side effect previous therapy You active infection require treatment You HIV positive history Hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>